Detaillierte Beitrags-Information
| Beitragstitel | 6-Month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE) |
|---|---|
| Beitragscode | P10 |
| Autor:innen | |
| Präsentationsform | Poster |
| Themengebiete |
|
| Abstract-Text |
Background: To evaluate effectiveness and tolerability of fremanezumab administered in migraine patients who switched from a previous anti-CGRP pathway mAb (aCGRP mAb) as part of their routine disease management. Material and Methods: FINESSE is an ongoing prospective, non-interventional study in adults with episodic or chronic migraine (EM, CM). Observation period: 24 months. Primary endpoint: proportion of patients reaching ≥ 50% reduction in average number of monthly migraine days (MMD) during the 6-month period after the first dose of fremanezumab. Further measures: monthly average number of migraine days, MIDAS (Migraine Disability Assessment), HIT-6 (6-Item Headache Impact Test), acute migraine medication (AMM) use. In this subgroup analysis, 6-month-data in patients who experienced poor effectiveness or tolerability with a prior anti-CGRP pathway mAb and therefore switched to fremanezumab are presented. Results: 140 patients with prior exposure to another aCGRP mAb were included (47.6 ± 11.5 years, 84.7% female); 56.4% had EM, 43.6 % CM. 126 patients had been previously treated with erenumab, 14 with galcanezumab or galcanezumab and erenumab. The main reason for discontinuation of prior aCGRP mAb therapy was lack of efficacy (LOE) in 110 patients (78.6%). MMD decreased from 13.3 ± 6.42 at baseline (B), by 6.1 ± 5.47 (month 6). 54 (38.6%) achieved a MMD reduction of ≥ 50% over 6 months (EM 44.3%, CM 31.2%, in patients with LOE 40%). AMM was used on 9.5 ± 4.92 days/month at baseline and decreased to 5.0 ± 3.86 days/month (month 6). MIDAS: 71.1 ± 57.1 (B), 43.7 ± 44.4 (month 6), HIT-6: 65.8 ± 4.8 (B), 59.6 ± 7.9 (month 6). Conclusions: In this interim analysis of the FINESSE non-interventional study, about 38.6% of anti-CGRP pathway mAb-non-responder benefit (≥ 50% response) from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing inadequate efficacy or poor tolerability with prior other anti-CGRP pathway mAb use. |